Trastuzumab Biosimilar Market Outlook:
Trastuzumab Biosimilar Market size was over USD 3.4 Billion in 2024 and is likely to exceed USD 15.8 Billion by the end of 2037, growing at over 18.9% CAGR during the forecast period i.e., between 2025-2037. In 2025, the industry size of trastuzumab biosimilar is assessed at USD 3.9 billion.
A growing number of patients in the trastuzumab biosimilar market are experiencing an increased number of positive breast and gastric cancer cases. As per the study of the World Health Organization, over 2 million new cases of breast cancer are diagnosed every year. Approximately 18% of the breast cancer cases are HER2-positive, which requires an intervention through trastuzumab biosimilars therapies. Betterment in the health care and improved diagnosis process resulted in an increase in the number of incidences of breast and gastric cancers. For instance, the emerging economy is the reason behind the rising incidence of breast and gastric cancer in Asia and Latin America, with the development diagnosis process in the advanced health infrastructure.
Furthermore, active pharmaceutical ingredients (APIs) are the most important raw material that is necessary for the production of trastuzumab biosimilars. India and China are the leading markets in supplying API in the global market. According to the 2023 USITC data report, more than 45% of the API is imported by the U.S. and Europe, and the finished products are regulated by the addressed trastuzumab biosimilar market. As per the information of the U.S. Bureau of Labor Statistics, the producer price index decreased by 12.5% for trastuzumab biosimilars, and the consumer price index rose by 5.5% for cancer biologics, which reflects the inflated supply chain cost. Besides, government investment for improved research and development is ensured through the allocation of approximately USD 651 million in 2023.
